CW May 2005

category image Volume 14
Issue Number 5
May 2005
ISSN 10593802

New Drug Delays Time to Progression in Previously Treated Multiple Myeloma Patients

Lenalidomide, an experimental oral drug not yet approved by the FDA, in combination with dexamethasone, more than doubled the response rate compared to dexamethasone alone in multiple myeloma patients with resistant disease.
Go to Previous Page
Go to Next Page

Source & Additional Reading

Donna Weber of The University of Texas MD Anderson Cancer Center in Houston, TX.

Report from the 41st Annual Meeting of the American Society of Clinical Oncology.

Purchase Downloadable Full-text PDF of Article: $10.00

Subscription is more cost effective than purchasing PDFs on-the-fly.  Click here for details.

Download Complete Issue CW May 2005

Purchase Downloadable Full-text PDF of Complete Issue: $20.00

Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us

Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA
phone: 518-456-0784; fax: 518-452-4955; email: info@adeninepress.com
copyright © Adeninepress, All rights reserved.




Re-initialize IP-based Login

Mountain Media ecommerce solutions Ecommerce Solutions by Mountain Media